key: cord-1055384-cibrw1z8
authors: Sullivan, H. Cliff; Roback, John D.
title: Convalescent Plasma: Therapeutic Hope or Hopeless Strategy in the SARS-CoV-2 Pandemic
date: 2020-04-23
journal: Transfus Med Rev
DOI: 10.1016/j.tmrv.2020.04.001
sha: 583bd048e2c150cca317e633e43cd04f76e59594
doc_id: 1055384
cord_uid: cibrw1z8

Abstract As the world faces the current SARS-CoV-2 pandemic, extensive efforts have been applied to identify effective therapeutic agents. Convalescent plasma collected from recovered patients has been a therapeutic modality employed for over a hundred years for various infectious pathogens. Specifically, it has been used in the treatment of many viral infections with varying degrees of clinical efficacy. As we consider the use of convalescent plasma in the battle against this new strain of coronavirus, it is prudent to review what is known from past experiences. Accordingly, the aim of this review is to examine in detail studies of convalescent plasma used during previous viral outbreaks and pandemics with particular focus on hemorrhagic fevers, influenza, and other coronaviruses. The concluding sections of this review address the potential use of convalescent plasma during the present-day SARS-CoV-2 pandemic, not only insofar as its clinical benefit but also the steps required to make convalescent plasma treatments readily available for an exponentially growing patient population. By the end, the authors hope to address the extent to which convalescent plasma represents a realistic therapeutic approach, or a distraction from other potentially useful treatments.

J o u r n a l P r e -p r o o f but rather PCR cycle threshold was used as a surrogate. Another key limitation was that at the time of transfusion, the anti-Ebola virus (EBOV) antibody and neutralizing antibody titers were not known. Subsequently, the same group published a follow-up letter to the editor with results of antibody testing. 12 Interestingly, patients receiving plasma with high doses of anti-EBOV IgG antibodies exhibited a correlation with larger decreases in viral loads. In terms of neutralizing antibodies, the majority (75%) of plasma donors had low titers (1:10 -1:40) and only a minority (5%) had high titers (1:160). These serological results bring the relevance of neutralizing antibody to the forefront and raise the important question of whether high levels of neutralizing antibody affect clinical efficacy.

The second nonrandomized study was out of Sierra Leone and compared clinical outcomes in 44 subjects treated with convalescent whole blood to 25 non-treated patients. 13 They showed an improvement in fatality in patients receiving convalescent whole blood compared to the control group (27.9% vs 44%, respectively) with a 2.3 odds ratio of survival for those receiving treatment. Although this study was not randomized, had a small n, and used whole blood as opposed to plasma, the results, unlike the previous study, suggest efficacy of convalescent blood products. The remaining Ebola-related publications are limited to case series that provide anecdotal efficacy of convalescent plasma in patients receiving at least one other investigational therapies, precluding definitive interpretation of the effects of convalescent plasma as a monotherapy. 14, 15 Notwithstanding the lack of overwhelming evidence, the WHO has recommended the investigation of convalescent plasma in the treatment of EVD and provided specific protocol guidelines. 16 This provision will hopefully propagate continued investigation, and recently, a prospective phase 1 trial was designed to assess the safety of pathogen reduced convalescent plasma in the treatment of EVD. 17 J o u r n a l P r e -p r o o f

Convalescent plasma has also been used in the setting of influenza, which is relevant to its application against coronavirus. Data on the use of convalescent plasma in the treatment of influenza dates back the 1918 H1N1 pandemic. A metanalysis of several related studies published between 1918 and 1925 revealed decreased case-fatality rate in the treated group vs the nontreated controls (16% vs. 37%, respectively); 18 there was also a difference in case-fatality rate noted in patients who received convalescent plasma early compared to those who were transfused later in their treatment course (19% vs 59%, respectively). None of the included studies were blinded or randomized and most contained heterogeneous and sometimes archaic treatment methods.

The randomized control trials that have been performed examining the efficacy of convalescent plasma concern influenza infection. Based on the promising results of their randomized, phase 2 trial, which investigated the utility of convalescent plasma versus standard of care in patients with severe influenza A or B, 19 Biegel and colleagues proceeded to carry out a prospective, randomized, double-blind phase 3 trial that sought to compare the clinical efficacy of convalescent plasma with high titer (≥1:80) anti-influenza A antibodies against convalescent plasma with low titer (≤1:10) anti-influenza A titers in patients with severe disease. 20 Patients were followed for 28 days with a primary end point being clinical status on day 7 as defined by a six-point ordinal scale. Ninety-two patients received high-titer plasma while 48 received low titer plasma. No benefit in high titer plasma over low titer plasma was found. In fact, the study was terminated early when it was determined that even if the planned full 150 participants were recruited, the high-titer group would still show no improvement in clinical status over low titer J o u r n a l P r e -p r o o f plasma. Of note, 34% of the subjects experienced serious adverse events including acute respiratory distress syndrome (ARDS) and allergic transfusion reactions, which highlight the potential hazards of convalescent plasma. Given the results and possible adverse reactions, the group concluded that the data did not warrant the treatment of influenza A with convalescent plasma.

Although this study had more patients than most published convalescent plasma studies, the overall number of patients included was only 138. Furthermore, they did not have a control group without plasma transfusion, as the investigators believed that a no-plasma control group would have affected the blinding because a saline infusion solution has a distinct appearance from plasma. The aforementioned phase 2 trial did assess high-titer plasma versus standard of care, and like the phase 3 trial, there was no significant benefit in plasma over standard treatment in terms of the primary endpoint. That being said, both the phase 2 and 3 trial indicated benefits in secondary endpoints, particularly in duration of mechanical ventilation and in intensive care.

Lastly, the phase 3 trial used hemagglutination inhibition titers as inclusion criteria for use of plasma. Some studies would contend that neutralizing antibody titers or anti-neuraminidase titers are more appropriate markers to measure. 21 Notwithstanding some of these limitations, this study represents the type of investigative design needed to properly evaluate the use of convalescent plasma.

During the influenza A (H1N1) pandemic of 2009, a prospective cohort study of adults with severe infection, requiring intensive care, was conducted. 22 In this study patients were offered convalescent plasma treatment and clinical outcomes were compared between those who accepted treatment and those who declined. In all, 93 patients were recruited of which 20 patients received convalescent plasma and were matched to the non-treatment control group. The J o u r n a l P r e -p r o o f group that received the convalescent plasma experienced significantly lower mortality than the control group (20.0% vs 54.8%, respectively), which remained significant in multivariate analysis. In addition to lower mortality, the treatment group saw significantly lower viral loads as well as lower cytokine levels post treatment. Even though this was not a randomized trial, it was prospective in nature with well-matched experimental and control groups and findings held up in multivariate models. When combining these findings with those from retrospective observational studies from the same period, 23 the use of convalescent plasma would seem to at least show potential in the setting of H1N1.

The 2006 avian influenza A/H5N1 outbreak and the 2015 outbreak influenza A (H7N9) mostly yielded case reports and cases series. [24] [25] [26] [27] Like the case reports from the Ebola experience, these reports suffer from the same limitations, including co-administration of other antivirals and treatments, particularly oseltamivir. Interestingly though, the investigator of one of these reports made a point to compare the viral sequences from the convalescent plasma donor and the patient and found > 99% homology. 25 This comparison addresses an important point for consideration when selecting convalescent donors, especially when there are multiple strains of influenza virus known to be in circulation.

Convalescent plasma can be fractionated into hyperimmune IV immunoglobulin (H-IVIG), a concentrated formulation with enriched levels of pathogen-specific antibodies. In regard to quality, the few studies that examine H-IVIG arguably supply some of the best designed studies of passive antibody transfer in human subjects. One such study was a multicenter, prospective, double-blind randomized control trial in the setting of the 2009 influenza A (H1N1) J o u r n a l P r e -p r o o f pandemic. 28 H-IVIG was manufactured from convalescent plasma from a total of 276 donors, all of whom had neutralizing antibody titers of > 1:40; and patients who received H-IVIG (n=17) had similar baseline demographics to and were compared to patients who received standard IVIG (n=18). The group that received H-IVIG had significantly lower viral loads on day 5 and 7 post infusion than the IVIG arm. Multivariate analysis revealed that treatment with H-IVIG was the only variable that reduced mortality (0% vs. 40%, experimental vs control group, respectively) when administered within 5 days of symptom onset.

Though this was a well-designed study, it is not without its limitations. The authors note that the fractionation process took approximately 6 months, and as such, the first wave of the pandemic was missed. By the time the study was carried out (2010 -2011), the pandemic started to dissipate, which negatively affected enrollment. Consequently, after exclusion criteria were applied, only 35 patients were included, limiting the power of the study. The generalizability of results is also limited, as the exclusion of late presentation precludes extrapolating data to a more critically ill subset of patients; and only donors with neutralizing antibody titers >1:40 were included. Thus, whether lower titer donors would offer any benefit remains unknown.

More recently in 2019, a multinational group, 45 institutions in all, published a randomized, double-blind, placebo-controlled trial investigating the safety and efficacy of H-IVIG in a cohort of adults patients over 5 influenza seasons. 29 Patients with symptom onset within 7 days of randomization and a National Early Warning score of at least 2 were randomized to either treatment groupstandard of care and 500 mL of H-HIVIGor control groupsaline placebo; study participants and investigators were blinded to treatment. The primary end point was a clinical outcome as defined by 6-category ordinal score at day 7, which was used to estimate odds ratio. After excluding patients that did not receive randomized J o u r n a l P r e -p r o o f treatments, 308 were included in analysis with 156 randomized to H-IVIG and 152 receiving placebo. Of the 308 patients, 224 had influenza A serotypes and 84 had influenza B serotypes.

The overall results showed that when administered with antiviral therapy the addition of H-IVIG did not demonstrate clinical improvement over placebo. The odds ratio of clinical improvement was 1.25 (95% CI: 0.79 -1.97, p=0.33). Death, serious adverse events, or grade 3 or 4 adverse events were 30% in each group. Notably, a pre-specified subgroup comparison of outcomes in influenza A and influenza B ran counter to the investigators' hypothesis. They found that the subgroup of patients with influenza A derived no benefit from treatment even though they achieved high titers of hemagglutinating antibody following infusion of H-IVIG. In contrast, the subgroup of patients with influenza B had improved clinical benefit at day 7 but achieved lower titers of antibody in response to infusion of H-IVIG. Post-study analysis found that the antibodies to influenza B had higher affinity. Yet, the data for influenza B are based on a small subset (n=84) of the total cohort (n=308) and therefore have wide confidence intervals.

Nevertheless, if H-IVIG were to demonstrate benefit in well-designed trials of SARS-CoV-2, H-IVIG may prove useful with regard to ease of administration compared with convalescent plasma. For example, H-IVIG volumes are generally small, simplifying distribution, and preparations could be administered via injection in outpatient settings as opposed to transfusion of plasma, which involves larger volumes delivered intravenously in a hospital type setting. 30

The use of convalescent plasma in the treatment of coronaviruses is not new. [31] [32] [33] and case series, 34 there are several retrospective, non-randomized studies that offer more substance.

Soo and colleagues compared 19 patients receiving convalescent plasma to 21 patients treated with pulsed methylprednisolone. 35 More subjects who received convalescent plasma were discharged by day 22 of hospitalization compared to the subjects in the steroid group (74% vs.

19%, respectively). Mortality was also lower in the convalescent plasma group, which had no deaths, whereas, five subjects in the steroid group died. The steroid group also had more cocomorbidities, but statistical significance between groups remained even after controlling for coexisting conditions. Nonetheless, this was a retrospective, non-randomized trial and similarly to some of the aforementioned Ebola studies, anti-SARS-CoV-1 antibodies contained within the convalescent plasma were not standardized; therefore, the degree to which antibody titer or type of antibodies present affect outcomes is unknown. The authors also questioned whether the poorer outcomes in the steroid group could have been due to the detrimental effects of steroids.

This theory is thought-provoking considering the current anecdotal observation that steroids may exacerbate disease in COVID-19 infection.

Cheng et al. examined the use of convalescent plasma from a different angle. They retrospectively reviewed 80 patients with SARS infection who had been given convalescent plasma (median volume 279.3 mL) and compared those who had been transfused before day 14 following the onset of symptoms to those who received plasma after day 14. 36 The results

showed that the group that received convalescent plasma earlier had better outcomes (defined as discharge by day 22 vs. death by day 22 or later discharge) than the patients who received 

In addition to Ebola, convalescent plasma has been evaluated in the treatment of other viral hemorrhagic fevers including Bolivian hemorrhagic fever, 41 Lassa fever, 42 and the Argentine hemorrhagic fever. 43 These studies were either small and/or suffered from poor design with numerous, non-controlled confounding factors. Of potential interest, one Lassa fever study was a controlled trial in which the investigators demonstrated improved mortality in patients who received convalescent plasma prior to day 10 of illness onset compared to those who received plasma after day 10 (9% vs 72%, respectively). 42 However, there are some caveats to this report.

This was a retrospective analysis that included cases spanning years starting in 1970, and variations in management that may have changed over the course of the years were not detailed.

Mortality of patients with Lassa fever who did not receive convalescent plasma was 27%, which is significantly better than those who received plasma after day 10. This could indicate a myriad of confounding factors including but not limited to: plasma after day 10 may have been detrimental, the group that received plasma later was sicker at baseline, or variation in medical management between patients.

Given the past experiences outlined above and the current threat of SARS-CoV-2, experts have proposed the potential clinical benefit of convalescent plasma in the management of COVID-19 infected patients. 1, 3, 7, 30, 44 To date though, only three case series of convalescent plasma in the setting of COVID-19 has been published from January -April of 2020 (See Table   1 for summary of reports). [45] [46] [47] In their cases series, Shen Though these reports provide some preliminary data suggesting benefit of convalescent plasma, conclusions should be drawn with caution as these reports share the same limitations as summarized in Table 2 Worth mentioning, a risk benefit analysis employing a stochastic age-specific susceptible-exposed-infected-removed (SEIR) model based on age, symptomatic/asymptomatic ratio, age-specific severity rates using comorbidity data, and COVID-19 transmission parameters was published in a recent review by Bloch and colleagues. 44 

When considering adding convalescent plasma to the current armamentarium in the fight against COVID-19 infection, the pros and cons must be weighed. The pros would include possible clinical efficacy, immediate availability from a large donor pool, relative ease of procuring plasma through current approved methods, and potential cost advantages over some of the more experimental antivirals. 50 Additionally, convalescent plasma may also offer prophylactic benefits, which could keep our healthcare workers on the frontlines remain healthy as well as prevent self-quarantine after exposure, which risks decreasing an already overstretched workforce. 7 Clinically, some investigators have attempted to assess the prophylactic potential of convalescent plasma, 51 but much more work is needed prior to drawing definitive conclusions.

The cons of convalescent plasma include basic administrative and logistical barriers of identifying, consenting, collecting, and testing donors. The efforts of the FDA delineated above should attenuate some of these hindrances. Finding donors with robust humoral response could be a hurdle as well, as not all recovered patients have detectable antibodies in the convalescent stage. 39, 52 Additionally, the current lack of widely available and validated SARS-CoV-2 antibody assays, particularly assays detecting neutralizing antibodies, may hamper identification of ideal donors. Concentrating for neutralizing activity may also mitigate potential viral antibody dependent enhancement (ADE), a process in which plasma antibodies exacerbate disease by enhancing viral cell entry and viral replication by various mechanisms, some of which have been described in MERS infectious model. 53, 54 Theoretically, ADE could exacerbate COVID-19 infection in patients who receive convalescent plasma from donors who were not tested for SARS-CoV-2 specific neutralizing antibodies. Moreover, the administration of passive J o u r n a l P r e -p r o o f antibodies can suppress the recipient's humoral immune system from generating pathogenspecific antibodies thereby leaving an individual susceptible to reinfection. 55 Of course, there is the rare but non-zero risk of transfusion transmitted infections.

However, pathogen reduction could improve the safety profile of convalescent plasma. In fact, one study found that psoralen treatment did not substantially reduce the titers of anti-EBOV specific antibodies or their neutralizing effect. 56 These findings are promising as they indicate that convalescent plasma can be safely modified to reduce infectious risk without disrupting possible efficacy. Finally, there are non-infectious hazards of transfusion. 57 Table 2 . Study limitations of 3 case series examining the use of convalescent plasma in the setting of SARS-CoV-2. -Limited powersmall patient populations (total n=19) -Poor generalizability of data -each report was based on a single institution's experience -Weak study designonly one of the three studies had a control group for comparison but it was a historical control group -Confounding factorsconcurrent treatment with steroids and antivirals -Timing of treatmentconvalescent plasma given relatively late in disease course (> day 10 in most cases) -Narrow inclusion criteriatreated patients limited to severely ill and/or critically ill patients

Evaluation and Treatment Coronavirus (COVID-19) StatPearls. Treasure Island (FL): StatPearls Publishing LLC

An interactive web-based dashboard to track COVID-19 in real time

Drug treatment options for the 2019-new coronavirus (2019-nCoV)

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial

The Trial of Chloroquine in the Treatment of Corona Virus Disease 2019 COVID-19 and Its Research Progress in Forensic Toxicology

Convalescent plasma as a potential therapy for COVID-19

The convalescent sera option for containing COVID-19

Passive antibody therapy for infectious diseases

Immunoglobulin prophylaxis in hematological malignancies and hematopoietic stem cell transplantation

Immunoglobulin prophylaxis in pediatric hematopoietic stem cell transplant

Evaluation of Convalescent Plasma for Ebola Virus Disease in Guinea

Convalescent Plasma and the Dose of Ebola Virus Antibodies

Evaluation of convalescent whole blood for treating Ebola Virus Disease in

Clinical Management of Ebola Virus Disease in the United States and Europe

The Use of TKM-100802 and Convalescent Plasma

Patients With Ebola Virus Disease in the United States

Use of Convalescent Whole Blood or Plasma Collected from Patients Recovered from Ebola Virus Disease for Transfusion, as an Empirical Treatment during Outbreaks. Interim Guidance for National Health Authorities and

A prospective, open label, phase 1 safety study of passive immune therapy during acute Ebola virus infection using transfusion of INTERCEPT plasma prepared from volunteer donors who have recovered from Ebola virus disease

Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment?

Immune plasma for the treatment of severe influenza: an open-label, multicentre, phase 2 randomised study

Anti-influenza immune plasma for the treatment of patients with severe influenza A: a randomised, double-blind, phase 3 trial

Evaluation of Antihemagglutinin and Antineuraminidase Antibodies as Correlates of Protection in an Influenza A/H1N1 Virus Healthy Human Challenge Model

Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection

Hong Kong's experience on the use of extracorporeal membrane oxygenation for the treatment of influenza A (H1N1)

Successful treatment of avian influenza with convalescent plasma

Treatment with convalescent plasma for influenza A (H5N1) infection

Successful treatment of avian-origin influenza A (H7N9) infection using convalescent plasma

Clinical characteristics of 26 human cases of highly pathogenic avian influenza A (H5N1) virus infection in China

Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A(H1N1) infection

Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-blind, randomised, placebo-controlled trial

Convalescent Plasma to Treat COVID-19: Possibilities and Challenges

Treatment of severe acute respiratory syndrome with convalescent plasma

Severe acute respiratory syndrome (SARS)

Epidemiologic features, clinical diagnosis and therapy of first cluster of patients with severe acute respiratory syndrome in Beijing area

Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital

Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients

Use of convalescent plasma therapy in SARS patients in Hong Kong

The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis

Comparative and kinetic analysis of and immunological responses in MERS patients representing a broad spectrum of disease severity

Kinetics of Serologic Responses to MERS Coronavirus Infection in Humans

Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection: a single centre experience

Bolivian hemorrhagic fever. A report of four cases

The use of Lassa fever convalescent plasma in Nigeria

Deployment of convalescent plasma for the prevention and treatment of COVID-19

Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. JAMA 2020

Effectiveness of convalescent plasma therapy in severe COVID-19 patients

Treatment with convalescent plasma for critically ill patients with SARS-CoV-2 infection

Covid-19: FDA approves use of convalescent plasma to treat critically ill patients

Recommendations for Investigational COVID-19 Convalescent Plasma

Convalescent transfusion for pandemic influenza: preparing blood banks for a new plasma product?

Use of Convalescent Measles Serum to Control Measles in a Preparatory School

Feasibility of Using Convalescent Plasma Immunotherapy for MERS-CoV Infection, Saudi Arabia

Antibody-dependent enhancement of virus infection and disease

Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry

Antibody formation. I. The suppression of antibody formation by passively administered antibody

Characterization of Ebola convalescent plasma donor immune response and psoralen treated plasma in the United States

Noninfectious serious hazards of transfusion